Biolife Solutions, Inc., a supplier of class-defining bioproduction tools and services for cell and gene therapies ("CGT"), and its biological material storage brand SciSafe, a multi-facility provider of storage services to the CGT and broader biopharma market, announced the opening of a new 40,000 square-foot biorepository Center of Excellence in Amsterdam, adjacent to the Schiphol Airport.
This facility, already partially contracted to an anchor major pharmaceutical customer, will include a CAR-T cell storage suite to support development of emerging CAR-T cell treatments, boasts a freezer farm of 300+ Stirling Ultracold ultra-low temperature ("ULT") freezers for biopreservation of customers' temperature sensitive biologic material. European pharmaceutical manufacturers are expanding their existing partnerships with SciSafe by utilizing this new Amsterdam storage facility to improve global access to lifesaving biologic therapies.
SciSafe's state-of-the-art and secure biostorage services allow clients' research teams to focus on what matters most – improving the lives of patients through the discovery of medicines that can prevent, treat and cure some of the world's most life-threatening diseases.
BioLife Solutions is leveraging its biopreservation tools and services portfolio (including Stirling Ultracold freezers, Isothermal freezers, CryoStor, HypoThermosol biopreservation media, ThawSTAR thawing equipment, evo Smart Shippers and Sexton cell processing tools) to define and support biostorage practices. SciSafe facilities hold various quality and regulatory certifications including: ISO20387 and ISO9001, FDA registration, Japan Pharma inspection and Farmatec accreditations.
Biolife Solutions is committed to ongoing infrastructure investments and innovation to maintain the integrity of stored customer biological and pharmaceutical assets 24/7/365, within its biostorage facilities. Cold storage solutions protect biologic materials in conditions ranging from +70°C to -196°C.
